Cyprus Institute of Neurology and Genetics Begins Clinical Phase of COMFORTage Project

Ahead of September 21 — World Alzheimer’s Day — the Cyprus Institute of Neurology and Genetics (Ινστιτούτο Νευρολογίας και Γενετικής Κύπρου, CING) announced the launch of the clinical phase of the COMFORTage study in Cyprus, aimed at early prognosis and prevention of dementia.

Individuals over 50 years old are invited to participate — both healthy and those with memory impairments. Assessments will be conducted by a neurologist, neuropsychologist, speech therapist, physiotherapist, and neurophysiologist. Participants’ results in Cyprus will be compared with data from other European countries.

At the same time, studies of the same format are being conducted in seven other countries to create comparable data sets. The collection covers clinical and molecular profiles of participants, including biochemical and molecular biomarkers, which will be analyzed using bioinformatics methods.

The results are expected to help develop models for organizing healthcare, allowing specialists to formulate dementia-related recommendations based on advanced research and individual patient profiles.

The COMFORTage project is funded by the European Union (Grant Number: 101137301). It involves scientists and researchers from 39 organizations in 12 countries, with CING leading one of the clinical research categories.